Abstract
<div class="authors authors-lg"><div class="author"><div class="author-img"><img src="https://cdn.insights.bio/uploads/Peter_Emtage-1566_proper_size copy 2.jpg" data-image="1"></div><div class="author-det"> <b>Peter Emtage</b> is a Venture Partner with Versant Ventures. Prior to joining Versant, Peter served as the Global Head of Cell Therapy Research at Kite Pharma, a Gilead company. Previous roles include Chief Scientific Officer at Cell Design Labs Inc., which was acquired by Gilead, and Vice President of Immune Mediated Therapy in the Oncology Innovative Medicines group at MedImmune. He has over 25 years of drug development experience in the fields of oncology, autoimmunity, infectious diseases, and inflammation. </div></div></div>
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
